GMP Human TNF-alpha Protein (Cat. No. GMP-TNAH23) is expressed in human 293 cells (HEK293) and comprises amino acids Val 77 to Leu 233 (Accession # P01375). This protein has no "tag". It has a ...
R Dr Eneas de Carvalho Aguiar 470, Instituto de Medicina Tropical (IMT), Cerqueira Cesar, São Paulo, SP, 05403 903, Brazil Tel.: +55 11 3061 7457 Fax: +55 11 3081 7190 mahong@usp.br Establishing that ...
BALTIMORE--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and ...
Study evaluates novel small molecule TNF-alpha inhibitor as potential alternative to biologic treatments NEW YORK--(BUSINESS WIRE)-- TNF Pharmaceuticals, Inc. (TNFA) (“TNF” or the “Company”), a ...
BALTIMORE--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and ...
TNF Pharmaceuticals (TNFA) announced that it has entered into a collaborative agreement with Renova Health for a planned trial of its TNF-alpha inhibitor drug isomyosamine as a treatment for ...
Genetic markers, specifically tumor necrosis factor alpha receptor 2 (TNFR2) gene polymorphisms, may predict response to TNF inhibitor therapy in patients with rheumatoid arthritis (RA). This approach ...
Transformative potential for novel TNF-alpha inhibitor drug: Estimated $40 billion TNF inhibitor market and $50 billion GLP-1 agonist market BALTIMORE--(BUSINESS WIRE)-- TNF Pharmaceuticals, Inc.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results